<DOC>
	<DOCNO>NCT00785408</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , parallel-group , dose-ranging study examine safety , tolerability , effect body weight subcutaneous AC2307 obese overweight subject .</brief_summary>
	<brief_title>Study Examine Safety , Tolerability Effect Body Weight Subcutaneous AC2307 Obese Overweight Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<criteria>Is obese body mass index ( BMI ) ≥30 kg/m^2 ≤45 kg/m^2 , overweight BMI ≥27 kg/m^2 &lt; 30 kg/m^2 least one weightrelated comorbidity ( dyslipidemia , impair fast glucose , hypertension , obstructive sleep apnea syndrome , polycystic ovary syndrome , and/or osteoarthritis ) Has major change daily physical activity ( e.g. , initiation exercise program ) enrol weight loss program within 2 month prior study start Has receive AC2307 pramlintide clinical study receive prior treatment pramlintide ( SYMLIN® ) calcitonin Has receive investigational drug within 1 month within period correspond five time halflife investigational drug , whichever great , study start Has donate blood within 2 month study start plan donate blood study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>obesity</keyword>
	<keyword>overweight</keyword>
	<keyword>weight loss</keyword>
	<keyword>Amylin</keyword>
	<keyword>AC2307</keyword>
</DOC>